Patent 8193211 was granted and assigned to Supernus Pharmaceuticals, Inc. on June, 2012 by the United States Patent and Trademark Office.
The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.